Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, Endocrinology & Metabolism, androgen receptor antagonist, antiandrogen, enzalutamide, bicalutamide, abiraterone, prostate cancer, LIGAND-BINDING DOMAIN, 3 BF3 SITE, CYPROTERONE-ACETATE, STRUCTURAL BASIS, PHASE-II, MEDROXYPROGESTERONE ACETATE, EUROPEAN-ORGANIZATION, ABIRATERONE ACETATE, DEPRIVATION THERAPY, LEUPROLIDE ACETATE, Androgen Receptor Antagonists, Animals, Antineoplastic Agents, Castration, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, 06 Biological Sciences, 11 Medical and Health Sciences, Oncology & Carcinogenesis, 3202 Clinical sciences, 3211 Oncology and carcinogenesis

Abstract:

Androgen deprivation is the mainstay therapy for metastatic prostate cancer (PCa). Another way of suppressing androgen receptor (AR) signaling is via AR antagonists or antiandrogens. Despite being frequently prescribed in clinical practice, there is conflicting evidence concerning the role of AR antagonists in the management of PCa. In the castration-resistant settings of PCa, docetaxel has been the only treatment option for decades. With recent evidence that castration-resistant PCa is far from AR-independent, there has been an increasing interest in developing new AR antagonists. This review gives a concise overview of the clinically available antiandrogens and the experimental AR antagonists that tackle androgen action with a different approach.